Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort
Publikation: Beitrag in Fachzeitschrift › Forschungsartikel › Beigetragen › Begutachtung
Beitragende
- Ludwig-Maximilians-Universität München (LMU)
- Otto-von-Guericke-Universität Magdeburg
- Universitätsklinikum Schleswig-Holstein Campus Kiel
- Johann Wolfgang Goethe-Universität Frankfurt am Main
- Julius-Maximilians-Universität Würzburg
- Universitätsklinikum Hamburg-Eppendorf (UKE)
- Christian-Albrechts-Universität zu Kiel (CAU)
- Klinik und Poliklinik für Kinder- und Jugendmedizin
- Universitätsklinikum Jena
- International Epidemiology Institute
- Martin-Luther-Universität Halle-Wittenberg
- Universität zu Köln
- Universitätsklinikum Würzburg
- Charité – Universitätsmedizin Berlin
Abstract
PURPOSE: We aimed to assess symptoms in patients after SARS-CoV-2 infection and to identify factors predicting prolonged time to symptom-free.
METHODS: COVIDOM/NAPKON-POP is a population-based prospective cohort of adults whose first on-site visits were scheduled ≥ 6 months after a positive SARS-CoV-2 PCR test. Retrospective data including self-reported symptoms and time to symptom-free were collected during the survey before a site visit. In the survival analyses, being symptom-free served as the event and time to be symptom-free as the time variable. Data were visualized with Kaplan-Meier curves, differences were tested with log-rank tests. A stratified Cox proportional hazard model was used to estimate adjusted hazard ratios (aHRs) of predictors, with aHR < 1 indicating a longer time to symptom-free.
RESULTS: Of 1175 symptomatic participants included in the present analysis, 636 (54.1%) reported persistent symptoms after 280 days (SD 68) post infection. 25% of participants were free from symptoms after 18 days [quartiles: 14, 21]. Factors associated with prolonged time to symptom-free were age 49-59 years compared to < 49 years (aHR 0.70, 95% CI 0.56-0.87), female sex (aHR 0.78, 95% CI 0.65-0.93), lower educational level (aHR 0.77, 95% CI 0.64-0.93), living with a partner (aHR 0.81, 95% CI 0.66-0.99), low resilience (aHR 0.65, 95% CI 0.47-0.90), steroid treatment (aHR 0.22, 95% CI 0.05-0.90) and no medication (aHR 0.74, 95% CI 0.62-0.89) during acute infection.
CONCLUSION: In the studied population, COVID-19 symptoms had resolved in one-quarter of participants within 18 days, and in 34.5% within 28 days. Over half of the participants reported COVID-19-related symptoms 9 months after infection. Symptom persistence was predominantly determined by participant's characteristics that are difficult to modify.
Details
Originalsprache | Englisch |
---|---|
Seiten (von - bis) | 1679-1694 |
Seitenumfang | 16 |
Fachzeitschrift | Infection |
Jahrgang | 51 |
Ausgabenummer | 6 |
Frühes Online-Datum | 25 Mai 2023 |
Publikationsstatus | Veröffentlicht - Dez. 2023 |
Peer-Review-Status | Ja |
Extern publiziert | Ja |
Externe IDs
PubMedCentral | PMC10212223 |
---|---|
Scopus | 85160410082 |
Schlagworte
Schlagwörter
- Adult, COVID-19/diagnosis, Female, Humans, Middle Aged, Prospective Studies, Retrospective Studies, Risk Factors, SARS-CoV-2